{"id":"high-dose-losartan","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperkalemia"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Cough"}]},"_chembl":{"chemblId":"CHEMBL382821","moleculeType":"Small molecule","molecularWeight":"467.92"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Losartan is an angiotensin II receptor blocker (ARB) that selectively antagonizes AT1 receptors, preventing angiotensin II-mediated vasoconstriction, aldosterone release, and sympathetic activation. At higher doses, it provides enhanced blood pressure reduction and may offer additional cardioprotective and renoprotective benefits beyond standard dosing.","oneSentence":"High-dose losartan blocks angiotensin II type 1 receptors to reduce blood pressure and provide cardiovascular protection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:47:41.983Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Heart failure"},{"name":"Diabetic nephropathy"},{"name":"Post-myocardial infarction cardioprotection"}]},"trialDetails":[{"nctId":"NCT03417388","phase":"PHASE4","title":"Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2018-02-09","conditions":"Coronary Artery Disease","enrollment":2476},{"nctId":"NCT04591210","phase":"PHASE3","title":"The COVID-RASi Trial (COVID-19)","status":"COMPLETED","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2021-01-27","conditions":"COVID-19, Cardiovascular Diseases","enrollment":372},{"nctId":"NCT06796660","phase":"EARLY_PHASE1","title":"Exploring the Impact of Nephropathy Formula No. 1 on Chronic Kidney Disease Patients","status":"NOT_YET_RECRUITING","sponsor":"Liu Zhanghong","startDate":"2025-09-01","conditions":"Renal Insufficiency, Chronic","enrollment":70},{"nctId":"NCT04662723","phase":"PHASE4","title":"Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.","status":"RECRUITING","sponsor":"Fondazione Schena","startDate":"2023-05-01","conditions":"Glomerulonephritis, Immunoglobulin A Nephropathy","enrollment":878},{"nctId":"NCT02235909","phase":"PHASE3","title":"An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension","status":"COMPLETED","sponsor":"Arbor Pharmaceuticals, Inc.","startDate":"2015-03-30","conditions":"Hypertension","enrollment":377},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT01307046","phase":"PHASE3","title":"MK-0954A in Japanese Patients With Essential Hypertension Not Adequately Controlled With Losartan (MK-0954A-352)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-03-29","conditions":"Hypertension","enrollment":336},{"nctId":"NCT04606563","phase":"PHASE3","title":"Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection?","status":"TERMINATED","sponsor":"University of British Columbia","startDate":"2020-10-09","conditions":"Covid19, SARS-CoV Infection","enrollment":341},{"nctId":"NCT03897868","phase":"PHASE2","title":"A Phase 2 Study to Assess Dose-response Relationship of HCP1803 in Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2019-03-21","conditions":"Hypertension","enrollment":248},{"nctId":"NCT04349410","phase":"PHASE2, PHASE3","title":"The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol","status":"COMPLETED","sponsor":"The Camelot Foundation","startDate":"2020-04-11","conditions":"CoVid 19 Positive","enrollment":1800},{"nctId":"NCT02744456","phase":"EARLY_PHASE1","title":"N-of-1 Trials for Blood Pressure Medications in Adults","status":"COMPLETED","sponsor":"Columbia University","startDate":"2014-08-01","conditions":"Hypertension, High Blood Pressure","enrollment":10},{"nctId":"NCT03505853","phase":"PHASE1","title":"A Study to Investigate the Interaction Between Givosiran and a 5-probe Drug Cocktail in Patients With Acute Intermittent Porphyria (AIP)","status":"COMPLETED","sponsor":"Alnylam Pharmaceuticals","startDate":"2018-04-26","conditions":"Acute Intermittent Porphyria (AIP), Acute Hepatic Porphyria (AHP), Porphyria, Acute Intermittent","enrollment":10},{"nctId":"NCT02238457","phase":"PHASE4","title":"Study of High Dosage of Losartan in Comparison to Low Dose of Losartan in Heart Failure Patients","status":"WITHDRAWN","sponsor":"Baker Heart and Diabetes Institute","startDate":"","conditions":"Heart Failure","enrollment":""},{"nctId":"NCT00223717","phase":"PHASE1","title":"Treatment of Supine Hypertension in Autonomic Failure","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2001-01","conditions":"Hypertension","enrollment":152},{"nctId":"NCT02269176","phase":"PHASE3","title":"Efficacy and Safety of Telmisartan and Losartan in Primary Hypertension","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2000-07","conditions":"Hypertension","enrollment":330},{"nctId":"NCT02200653","phase":"PHASE4","title":"A Trial Comparing MICARDIS® (Telmisartan) and COZAAR® / LORZAAR® (Losartan) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring (ABPM)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2000-05","conditions":"Hypertension","enrollment":387},{"nctId":"NCT02200640","phase":"PHASE4","title":"A Trial Comparing MICARDIS® (Telmisartan) and COZAAR® (Losartan) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring (ABPM)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2000-03","conditions":"Hypertension","enrollment":333},{"nctId":"NCT01570569","phase":"PHASE1","title":"Development of Minidose Inje Cocktail Method for Simultaneous Evaluating Five Cytochrome P450 Isoforms in Human","status":"COMPLETED","sponsor":"Inje University","startDate":"2011-01","conditions":"Healthy","enrollment":26},{"nctId":"NCT00795847","phase":"PHASE4","title":"Morning Hypertension and Preminent Therapy Study","status":"COMPLETED","sponsor":"Kurume University","startDate":"2008-11","conditions":"Hypertension","enrollment":216},{"nctId":"NCT01197014","phase":"PHASE1","title":"A Bioequivalence Study of Amlodipine Plus Losartan Versus Amlodipine and Losartan","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2010-09","conditions":"Healthy","enrollment":72}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Losartan (Cozaar)"],"phase":"marketed","status":"active","brandName":"High dose losartan","genericName":"High dose losartan","companyName":"Baker Heart and Diabetes Institute","companyId":"baker-heart-and-diabetes-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"High-dose losartan blocks angiotensin II type 1 receptors to reduce blood pressure and provide cardiovascular protection. Used for Hypertension, Heart failure, Diabetic nephropathy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}